Realistic efficacy of oxymetholone in comparison to rabbit-antithymocyte globulin for severe acquired aplastic anemia: a retrospective study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20211208002

Enrollment

Registered

2021-12-08

Start date

2019-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Real-world response of oxymetholone compared with rabbit anti-thymocyte globulin plus cyclosporine in severe and very severe acquired aplastic anemia Acquired aplastic anemia, oxymetholone, anti-thymocyte globulin

Interventions

Patients with SAA and vSAA who treated with oxymetholone,Patients with SAA and vSAA who treated with rabbit ATG plus cyclosporine

Treatment,Treatment

Oxymetholone,rabbit ATG

Eligibility

Sex/Gender

All

Age

15 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Patients were diagnosed with idiopathic SAA or vSAA. 2) received initial treatment with oxymetholone or rATG/CsA at Songklanagarind hospital between January 2004 and December 2019.

Exclusion criteria

Exclusion criteria: 1) Patients died within the first month after beginning treatment. 2) Patients were diagnosed with drug-induced AA. 3) Patients had incomplete data of diagnosis or treatment.

Design outcomes

Primary

Measure	Time frame
Overall response 2 years after the beginning of treatment Response rate	—

Secondary

Measure	Time frame
Overall survival 2 years after the beginning of treatment Kaplan-Meier method	—

Countries

Thailand

Contacts

Public ContactPrapaporn Pengthina

Department of Pharmaceutical care, Faculty of Pharmacy, Chiang Mai University

prapaporn.pengthina@cmu.ac.th66903186788

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026